{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:13:13Z","timestamp":1757452393075,"version":"3.37.3"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1124\/molpharm.121.000254","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T22:05:14Z","timestamp":1621893914000},"page":"144-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin"],"prefix":"10.1016","volume":"100","author":[{"given":"Trista K.","family":"Hinz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshni","family":"Kalkur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Rabinovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyatt","family":"Hinkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn E.","family":"Heasley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.121.000254_bib1","doi-asserted-by":"crossref","first-page":"15882","DOI":"10.1016\/S0021-9258(18)98491-7","article-title":"Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data","volume":"266","author":"Bai","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1124\/molpharm.121.000254_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/molpharm.121.000254_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106131","article-title":"Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells","volume":"9","author":"Dezs\u0151","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.121.000254_bib4","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1016\/j.celrep.2019.08.061","article-title":"Integrated analysis of TP53 gene and pathway alterations in the Cancer Genome Atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"10.1124\/molpharm.121.000254_bib5","article-title":"Targeting p53 for the treatment of cancer","author":"Duffy","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1124\/molpharm.121.000254_bib6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/JTO.0b013e31823f43ca","article-title":"A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial","volume":"7","author":"Gitlitz","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1124\/molpharm.121.000254_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/cgt.2010.63","article-title":"Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies","volume":"18","author":"Goldstein","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1124\/molpharm.121.000254_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/14656566.2017.1316374","article-title":"Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer","volume":"18","author":"Hardin","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/molpharm.121.000254_bib9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2018.02.001","article-title":"Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy","volume":"118","author":"Helfrich","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1124\/molpharm.121.000254_bib10","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/annonc\/mdx284","article-title":"A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician\u2019s choice in patients with advanced non-small cell lung cancer","volume":"28","author":"Katakami","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1124\/molpharm.121.000254_bib11","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1124\/molpharm.121.000254_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009318","article-title":"Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin","volume":"6","author":"Laughney","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1124\/molpharm.121.000254_bib13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/molpharm.121.000254_bib14","doi-asserted-by":"crossref","first-page":"70011","DOI":"10.18632\/oncotarget.11727","article-title":"ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines","volume":"7","author":"Oba","year":"2016","journal-title":"Oncotarget"},{"key":"10.1124\/molpharm.121.000254_bib15","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026336","article-title":"The role of MDM2 amplification and overexpression in tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1124\/molpharm.121.000254_bib16","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1124\/molpharm.121.000254_bib17","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"Oren","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1124\/molpharm.121.000254_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fonc.2019.00195","article-title":"A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer","volume":"9","author":"Pacheco","year":"2019","journal-title":"Front Oncol"},{"key":"10.1124\/molpharm.121.000254_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jcb.240630505","article-title":"NCI-Navy Medical Oncology Branch cell line data base","volume":"24","author":"Phelps","year":"1996","journal-title":"J Cell Biochem Suppl"},{"key":"10.1124\/molpharm.121.000254_bib20","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/1078-0432.CCR-14-2748","article-title":"Lung cancer in the era of precision medicine","volume":"21","author":"Politi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1124\/molpharm.121.000254_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1124\/molpharm.121.000254_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cllc.2011.06.010","article-title":"A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer","volume":"13","author":"Spira","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1124\/molpharm.121.000254_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/13543784.2017.1292250","article-title":"Eribulin in non-small cell lung cancer: challenges and potential strategies","volume":"26","author":"Swami","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/molpharm.121.000254_bib24","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/molpharm.121.000254_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1124\/molpharm.121.000254_bib26","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","article-title":"FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies","volume":"20","author":"Wynes","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1124\/molpharm.121.000254_bib27","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jmb.2017.03.030","article-title":"Mutant p53 in cancer: accumulation, gain-of-function, and therapy","volume":"429","author":"Yue","year":"2017","journal-title":"J Mol Biol"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24011520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.121.000254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:46:30Z","timestamp":1739954790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24011520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0026895X24011520"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.121.000254","relation":{},"ISSN":["0026-895X"],"issn-type":[{"type":"print","value":"0026-895X"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.121.000254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}